Advertising

TSE:PLI

13.60
0.03 (0.22%) 1d
0
Showing 1 to 15 of 77 entries
DON'T BUY
They hit a financing crisis and needed cash. So, they issued 20 billion share at 1.5 cents per share. A massive dilution that destroyed the shareholder base. Avoid.
biotechnology / pharmaceutical
SELL
Technically, the new low at 8 cents does not offer anything meaningful. He would look at tax loss selling. Take the tax loss and move on.
biotechnology / pharmaceutical
SELL
He has followed this for a long time. It extracts protein from blood plasma and a drug that treats inflammation. They have added massive debt -- about $250 billion. He thinks there will be dramatic issues ahead and it will not end well for common shareholders.
biotechnology / pharmaceutical
DON'T BUY
The recent significant fall of 22% last week, would not be a signal to buy. He would stay away.
biotechnology / pharmaceutical
WAIT
The big challenge is getting their product to market. They have most of the cash they need into 2020, which should buy them enought time. He is watching to see how revenues ramp up next year.
biotechnology / pharmaceutical
SELL
He has been disappointed in the company but in clinical trials and the FDA process, things don't go as well as you want. They ran into a cash crush so they extended the terms of their debt. It is way down and the time-frame is extended. You should move on. There is tax loss selling.
biotechnology / pharmaceutical
DON'T BUY

The key is their ability to take a bag of plasma and extract a bunch of proteins. They can sell as much as they can produce. The market is concerned about their spending in R&D. It appears to be a long way away from payday.

biotechnology / pharmaceutical
DON'T BUY

They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position.

biotechnology / pharmaceutical
SELL

He is short this company presently. The market cap is quite high compared to his estimate of value. The company appears to be quite promotional compared to others. Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage. He does not see revenues and earnings to back it up.

biotechnology / pharmaceutical
WATCH

He believes this has been very volatile due to an overhang and the potential need for more financing. It is stabilizing now and they have received an investment from the Thompson family. He thinks they should begin to receive approval soon with sales later this year. They do not own it presently, although they have held it in the past.

biotechnology / pharmaceutical
COMMENT

Prometic has two parts to its business. They can buy a bag of plasma for $200US and extract 11-13 high profile proteins. They have already applied to do 4 of those. There is an almost unlimited market for one of those, plasminogen, because there is no other supply of it. They’re also working on another drug that targets fibrosis. The studies for this drug are very costly, so PLI has had to raise a lot of capital. This will take a long time, is very risky, but will pay off well if successful. They are expected to break even next year based on their protein extraction.

biotechnology / pharmaceutical
COMMENT

The near to intermediate term is a bit of a challenge. They have technology to extract proteins from a bag of plasma. Their specialty is that they require a lot less CapX and operating costs to do it, and can end up getting much higher yields. The current process, which is over 40 years old, is maximized and optimized for something totally different in the proteins they were getting. They have approval to get plasminogen. Spending a ton of money to go through the formal drug testing process. It’s not expected to earn any money in 2018, but a loss of $.13 a share. Expected to break even in 2019.

biotechnology / pharmaceutical
COMMENT

Doing interesting drug trials, with a near-term opportunity for their orphan drug Placminogen, a specialty protein. With Placminogen they can basically sell almost everything they can produce. Earnings estimates for 2019 is basically zero. You are buying this for 2 reasons. 1.) The manufacturing process; buying a bag of plasma for $120, breaking out a large number of proteins, and selling it over time for about $1000. 2.) their drug PBI4050 which is targeted towards fibrosis, where early results are quite positive. To develop a drug and go through phase 2 and 3 drug trials, is extremely expensive. If your time frame is 3 years, he thinks you will be happy. A speculative company working with some very interesting drug opportunities.

biotechnology / pharmaceutical
COMMENT

This does blood plasma protein. It is something that has been very easy for them to get FDA approval for their treatments. However, revenues and cash flow just haven’t come as they promised in the past. Did a pretty dilutive equity raise recently, which didn’t go that well. He is Short this, and probably will stay Short until the stock from the equity deal gets cleaned up.

biotechnology / pharmaceutical
HOLD

They are going to have a lot of catalysts between now and Q1 2018 on their drugs and some of their trials. He sold it higher up for technical reasons. He would hold onto it because of the catalysts.

biotechnology / pharmaceutical
Showing 1 to 15 of 77 entries

Prometic Life Sciences Inc.(PLI-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Prometic Life Sciences Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Prometic Life Sciences Inc.(PLI-T) Frequently Asked Questions

What is Prometic Life Sciences Inc. stock symbol?

Prometic Life Sciences Inc. is a Canadian stock, trading under the symbol PLI-T on the Toronto Stock Exchange (PLI-CT). It is usually referred to as TSX:PLI or PLI-T

Is Prometic Life Sciences Inc. a buy or a sell?

In the last year, there was no coverage of Prometic Life Sciences Inc. published on Stockchase.

Is Prometic Life Sciences Inc. a good investment or a top pick?

Prometic Life Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Prometic Life Sciences Inc..

Why is Prometic Life Sciences Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Prometic Life Sciences Inc. worth watching?

0 stock analysts on Stockchase covered Prometic Life Sciences Inc. In the last year. It is a trending stock that is worth watching.

What is Prometic Life Sciences Inc. stock price?

On 2019-10-04, Prometic Life Sciences Inc. (PLI-T) stock closed at a price of $13.6.